Creo Medical Regulatory News (CREO)

Creo Medical Group plc

("Creo" or the "Company")

Issue of Equity

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has made an application for 3,000,000 new Ordinary Shares to be admitted to trading on AIM.

These new Ordinary Shares will be held by the Company's Employee Benefit Trust ("EBT") and will be used to satisfy exercises of shares currently under option, as well as for future LTIP awards. The voting rights on these new Ordinary Shares will be exercisable by the trustee of the EBT ("Trustee") at its sole discretion. Application will be made for 3,000,000 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 7 July 2021. Following the allotment and issue, the Company's issued share capital consists of 160,940,390 Ordinary Shares. The Company does not hold any shares in Treasury, as such the total number of shares in issue with voting rights is 160,940,390.

The above figure of 160,940,390 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquires:

About Creo Medical 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed the CROMA Advanced Energy Platform powered by Kamaptive™ full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive™ is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive™ technology provides clinicians with increased flexibility, precision and controlled surgical solutions. 

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by Kamaptive™ technology to market, enabling a wide range of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy Platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. 

For more information about Creo Medical please see our website, investors.creomedical.com